Aquestive Therapeutics settles patent infringement case with Par Pharmaceuticals
WARREN, N.J. — Specialty pharmaceutical company Aquestive Therapeutics has reached a settlement agreement resolving patent litigation related to Suboxone (buprenorphine and naloxone) Sublingual Film.
Indivior, a marketer and distributor of Suboxone, joined Aquestive in the settlement with Par Pharmaceuticals, an operating company of Endo International and IntelGenx Technologies Corp.
Under the settlement agreement, Par Pharmaceuticals and IntelGenx agreed to launch their proposed generic version of the buprenorphine and naloxone sublingual film no earlier than Jan. 1, 2023. The patent-infringement litigation has been pending in the U.S. District Court for the District of Delaware. As required by law, the parties will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.
“This settlement once again demonstrates the value our intellectual property and know-how represent for us and our partners,” stated Keith Kendall, CEO of Aquestive. “We will continue to focus our PharmFilm technology platform on innovating within difficult disease states such as epilepsy, Parkinson’s and ALS.”
No comments found